Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy
Huntington’s Disease (HD) is a dominantly inherited neurodegenerative disease for which the major causes of mortality are neurodegeneration-associated aspiration pneumonia followed by cardiac failure. mTORC1 pathway perturbations are present in HD models and human tissues. Amelioration of mTORC1 def...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423655/?tool=EBI |
| _version_ | 1828144403526451200 |
|---|---|
| author | Sophie St-Cyr Daniel D. Child Emilie Giaime Alicia R. Smith Christine J. Pascua Seung Hahm Eddine Saiah Beverly L. Davidson |
| author_facet | Sophie St-Cyr Daniel D. Child Emilie Giaime Alicia R. Smith Christine J. Pascua Seung Hahm Eddine Saiah Beverly L. Davidson |
| author_sort | Sophie St-Cyr |
| collection | DOAJ |
| description | Huntington’s Disease (HD) is a dominantly inherited neurodegenerative disease for which the major causes of mortality are neurodegeneration-associated aspiration pneumonia followed by cardiac failure. mTORC1 pathway perturbations are present in HD models and human tissues. Amelioration of mTORC1 deficits by genetic modulation improves disease phenotypes in HD models, is not a viable therapeutic strategy. Here, we assessed a novel small molecule mTORC1 pathway activator, NV-5297, for its improvement of the disease phenotypes in the N171-82Q HD mouse model. Oral dosing of NV-5297 over 6 weeks activated mTORC1, increased striatal volume, improved motor learning and heart contractility. Further, the heart contractility, heart fibrosis, and survival were improved in response to the cardiac stressor isoprenaline when compared to vehicle-treated mice. Cummulatively, these data support mTORC1 activation as a therapeutic target in HD and consolidates NV-5297 as a promising drug candidate for treating central and peripheral HD phenotypes and, more generally, mTORC1-deficit related diseases. |
| first_indexed | 2024-04-11T20:14:26Z |
| format | Article |
| id | doaj.art-16514b579452461bb2a16355f8185afa |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T20:14:26Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-16514b579452461bb2a16355f8185afa2022-12-22T04:05:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01178Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapySophie St-CyrDaniel D. ChildEmilie GiaimeAlicia R. SmithChristine J. PascuaSeung HahmEddine SaiahBeverly L. DavidsonHuntington’s Disease (HD) is a dominantly inherited neurodegenerative disease for which the major causes of mortality are neurodegeneration-associated aspiration pneumonia followed by cardiac failure. mTORC1 pathway perturbations are present in HD models and human tissues. Amelioration of mTORC1 deficits by genetic modulation improves disease phenotypes in HD models, is not a viable therapeutic strategy. Here, we assessed a novel small molecule mTORC1 pathway activator, NV-5297, for its improvement of the disease phenotypes in the N171-82Q HD mouse model. Oral dosing of NV-5297 over 6 weeks activated mTORC1, increased striatal volume, improved motor learning and heart contractility. Further, the heart contractility, heart fibrosis, and survival were improved in response to the cardiac stressor isoprenaline when compared to vehicle-treated mice. Cummulatively, these data support mTORC1 activation as a therapeutic target in HD and consolidates NV-5297 as a promising drug candidate for treating central and peripheral HD phenotypes and, more generally, mTORC1-deficit related diseases.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423655/?tool=EBI |
| spellingShingle | Sophie St-Cyr Daniel D. Child Emilie Giaime Alicia R. Smith Christine J. Pascua Seung Hahm Eddine Saiah Beverly L. Davidson Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy PLoS ONE |
| title | Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy |
| title_full | Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy |
| title_fullStr | Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy |
| title_full_unstemmed | Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy |
| title_short | Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy |
| title_sort | huntington s disease phenotypes are improved via mtorc1 modulation by small molecule therapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423655/?tool=EBI |
| work_keys_str_mv | AT sophiestcyr huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy AT danieldchild huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy AT emiliegiaime huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy AT aliciarsmith huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy AT christinejpascua huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy AT seunghahm huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy AT eddinesaiah huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy AT beverlyldavidson huntingtonsdiseasephenotypesareimprovedviamtorc1modulationbysmallmoleculetherapy |